{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T06:26:39Z","timestamp":1781677599600,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:00:00Z","timestamp":1578009600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:00:00Z","timestamp":1578009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100005378","name":"Hacettepe \u00dcniversitesi","doi-asserted-by":"crossref","award":["H.U. Scientific Research Projects Coordination Unit, TTU-2017- 15644"],"award-info":[{"award-number":["H.U. Scientific Research Projects Coordination Unit, TTU-2017- 15644"]}],"id":[{"id":"10.13039\/501100005378","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s00345-019-03065-2","type":"journal-article","created":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T20:02:25Z","timestamp":1578081745000},"page":"2537-2545","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6047-8431","authenticated-orcid":false,"given":"Ahmet Murat","family":"Aydin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek E.","family":"Baydar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berk","family":"Hazir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berrin","family":"Babaoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cenk Y.","family":"Bilen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,3]]},"reference":[{"issue":"3","key":"3065_CR1","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"M Babjuk","year":"2017","unstructured":"Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM, Hernandez V, Kaasinen E, Palou J, Roupret M, van Rhijn BW, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71(3):447\u2013461. https:\/\/doi.org\/10.1016\/j.eururo.2016.05.041","journal-title":"Eur Urol"},{"issue":"1","key":"3065_CR2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","volume":"69","author":"S Cambier","year":"2016","unstructured":"Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G, Kirkels WJ, Silva FC, Oosterlinck W, Prescott S, Kirkali Z, Powell PH, de Reijke TM, Turkeri L, Collette S, Oddens J (2016) EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1\u20133 years of maintenance Bacillus Calmette-Guerin. Eur Urol 69(1):60\u201369. https:\/\/doi.org\/10.1016\/j.eururo.2015.06.045","journal-title":"Eur Urol"},{"issue":"3","key":"3065_CR3","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2016.06.020","volume":"71","author":"J Alfred Witjes","year":"2017","unstructured":"Alfred Witjes J, Lebret T, Comperat EM, Cowan NC, De Santis M, Bruins HM, Hernandez V, Espinos EL, Dunn J, Rouanne M, Neuzillet Y, Veskimae E, van der Heijden AG, Gakis G, Ribal MJ (2017) Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 71(3):462\u2013475. https:\/\/doi.org\/10.1016\/j.eururo.2016.06.020","journal-title":"Eur Urol"},{"issue":"10","key":"3065_CR4","doi-asserted-by":"publisher","first-page":"5538","DOI":"10.4049\/jimmunol.169.10.5538","volume":"169","author":"T Yamazaki","year":"2002","unstructured":"Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, Shin T, Tsuchiya H, Pardoll DM, Okumura K, Azuma M, Yagita H (2002) Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 169(10):5538\u20135545","journal-title":"J Immunol"},{"key":"3065_CR5","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3389\/fimmu.2017.00961","volume":"8","author":"RM Gibbons Johnson","year":"2017","unstructured":"Gibbons Johnson RM, Dong H (2017) Functional expression of programmed death-ligand 1 (B7\u2013H1) by immune cells and tumor cells. Front Immunol 8:961. https:\/\/doi.org\/10.3389\/fimmu.2017.00961","journal-title":"Front Immunol"},{"issue":"1","key":"3065_CR6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1600-065X.2009.00767.x","volume":"229","author":"JL Riley","year":"2009","unstructured":"Riley JL (2009) PD-1 signaling in primary T cells. Immunol Rev 229(1):114\u2013125. https:\/\/doi.org\/10.1111\/j.1600-065X.2009.00767.x","journal-title":"Immunol Rev"},{"issue":"11","key":"3065_CR7","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/phar.2033","volume":"37","author":"KS Hanna","year":"2017","unstructured":"Hanna KS (2017) a review of immune checkpoint inhibitors for the management of locally advanced or metastatic urothelial carcinoma. Pharmacotherapy 37(11):1391\u20131405. https:\/\/doi.org\/10.1002\/phar.2033","journal-title":"Pharmacotherapy"},{"issue":"11","key":"3065_CR8","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1080\/14712598.2017.1366445","volume":"17","author":"M Boegemann","year":"2017","unstructured":"Boegemann M, Aydin AM, Bagrodia A, Krabbe LM (2017) Prospects and progress of immunotherapy for bladder cancer. Expert Opin Biol Ther 17(11):1417\u20131431. https:\/\/doi.org\/10.1080\/14712598.2017.1366445","journal-title":"Expert Opin Biol Ther"},{"key":"3065_CR9","volume-title":"WHO Classification of tumours of the urinary system and male genital organs","author":"H Moch","year":"2016","unstructured":"Moch H, Humphrey PA, Ulbright TM, Reuter V (2016) WHO Classification of tumours of the urinary system and male genital organs. International Agency for Research on Cancer, Lyon, France"},{"issue":"10031","key":"3065_CR10","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387(10031):1909\u20131920. https:\/\/doi.org\/10.1016\/S0140-6736(16)00561-4","journal-title":"Lancet"},{"issue":"4","key":"3065_CR11","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1464-410X.2010.09572.x","volume":"107","author":"DM Kakiashvili","year":"2011","unstructured":"Kakiashvili DM, van Rhijn BW, Trottier G, Jewett MA, Fleshner NE, Finelli A, Azuero J, Bangma CH, Vajpeyi R, Alkhateeb S, Hanna S, Kostynsky A, Kuk C, Van Der Kwast TH, Zlotta AR (2011) Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guerin treatment. BJU Int 107(4):540\u2013546. https:\/\/doi.org\/10.1111\/j.1464-410X.2010.09572.x","journal-title":"BJU Int"},{"issue":"6","key":"3065_CR12","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0302-2838(02)00173-2","volume":"41","author":"JJ Patard","year":"2002","unstructured":"Patard JJ, Rodriguez A, Leray E, Rioux-Leclercq N, Guille F, Lobel B (2002) Intravesical Bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours. Eur Urol 41(6):635\u2013641 (discussion 642)","journal-title":"Eur Urol"},{"issue":"8","key":"3065_CR13","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s00262-006-0266-z","volume":"56","author":"J Nakanishi","year":"2007","unstructured":"Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S (2007) Overexpression of B7\u2013H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother 56(8):1173\u20131182. https:\/\/doi.org\/10.1007\/s00262-006-0266-z","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"3065_CR14","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00262-017-2093-9","volume":"67","author":"J Breyer","year":"2018","unstructured":"Breyer J, Wirtz RM, Otto W, Erben P, Worst TS, Stoehr R, Eckstein M, Denzinger S, Burger M, Hartmann A (2018) High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients. Cancer Immunol Immunother 67(3):403\u2013412. https:\/\/doi.org\/10.1007\/s00262-017-2093-9","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"3065_CR15","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.7314\/APJCP.2014.15.3.1321","volume":"15","author":"YH Wang","year":"2014","unstructured":"Wang YH, Cao YW, Yang XC, Niu HT, Sun LJ, Wang XS, Liu J (2014) Effect of TLR4 and B7\u2013H1 on immune escape of urothelial bladder cancer and its clinical significance. Asian Pac J Cancer Prev 15(3):1321\u20131326","journal-title":"Asian Pac J Cancer Prev"},{"key":"3065_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13887","author":"B Wang","year":"2018","unstructured":"Wang B, Pan W, Yang M, Yang W, He W, Chen X, Bi J, Jiang N, Huang J, Lin T (2018) Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder. Cancer Sci. https:\/\/doi.org\/10.1111\/cas.13887","journal-title":"Cancer Sci"},{"issue":"3","key":"3065_CR17","doi-asserted-by":"publisher","first-page":"e701","DOI":"10.1016\/j.urology.2014.10.020","volume":"85","author":"SF Faraj","year":"2015","unstructured":"Faraj SF, Munari E, Guner G, Taube J, Anders R, Hicks J, Meeker A, Schoenberg M, Bivalacqua T, Drake C, Netto GJ (2015) Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma. Urology 85(3):e701\u2013e706. https:\/\/doi.org\/10.1016\/j.urology.2014.10.020","journal-title":"Urology"},{"issue":"5","key":"3065_CR18","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.urolonc.2017.01.014","volume":"35","author":"C Le Goux","year":"2017","unstructured":"Le Goux C, Damotte D, Vacher S, Sibony M, Delongchamps NB, Schnitzler A, Terris B, Zerbib M, Bieche I, Pignot G (2017) Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: a retrospective study. Urol Oncol 35(5):257\u2013263. https:\/\/doi.org\/10.1016\/j.urolonc.2017.01.014","journal-title":"Urol Oncol"},{"issue":"4","key":"3065_CR19","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.juro.2017.04.102","volume":"198","author":"SAM Wankowicz","year":"2017","unstructured":"Wankowicz SAM, Werner L, Orsola A, Novak J, Bowden M, Choueiri TK, de Torres I, Morote J, Freeman GJ, Signoretti S, Bellmunt J (2017) Differential expression of PD-L1 in high grade T1 vs muscle invasive bladder carcinoma and its prognostic implications. J Urol 198(4):817\u2013823. https:\/\/doi.org\/10.1016\/j.juro.2017.04.102","journal-title":"J Urol"},{"issue":"8","key":"3065_CR20","doi-asserted-by":"publisher","first-page":"1602460","DOI":"10.1080\/2162402X.2019.1602460","volume":"8","author":"R Martinez","year":"2019","unstructured":"Martinez R, Tapia G, De Muga S, Hernandez A, Cao MG, Teixido C, Urrea V, Garcia E, Pedreno-Lopez S, Ibarz L, Blanco J, Clotet B, Cabrera C (2019) Combined assessment of peritumoral Th1\/Th2 polarization and peripheral immunity as a new biomarker in the prediction of BCG response in patients with high-risk NMIBC. Oncoimmunology 8(8):1602460. https:\/\/doi.org\/10.1080\/2162402X.2019.1602460","journal-title":"Oncoimmunology"},{"issue":"15","key":"3065_CR21","doi-asserted-by":"publisher","first-page":"4800","DOI":"10.1158\/1078-0432.CCR-08-0731","volume":"14","author":"SA Boorjian","year":"2008","unstructured":"Boorjian SA, Sheinin Y, Crispen PL, Farmer SA, Lohse CM, Kuntz SM, Leibovich BC, Kwon ED, Frank I (2008) T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res 14(15):4800\u20134808. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-0731","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3065_CR22","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/cncr.22588","volume":"109","author":"BA Inman","year":"2007","unstructured":"Inman BA, Sebo TJ, Frigola X, Dong H, Bergstralh EJ, Frank I, Fradet Y, Lacombe L, Kwon ED (2007) PD-L1 (B7\u2013H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 109(8):1499\u20131505. https:\/\/doi.org\/10.1002\/cncr.22588","journal-title":"Cancer"},{"issue":"75","key":"3065_CR23","doi-asserted-by":"publisher","first-page":"34066","DOI":"10.18632\/oncotarget.26122","volume":"9","author":"A Hashizume","year":"2018","unstructured":"Hashizume A, Umemoto S, Yokose T, Nakamura Y, Yoshihara M, Shoji K, Wada S, Miyagi Y, Kishida T, Sasada T (2018) Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin. Oncotarget 9(75):34066\u201334078. https:\/\/doi.org\/10.18632\/oncotarget.26122","journal-title":"Oncotarget"},{"key":"3065_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-019-02896-3","author":"C Delcourt","year":"2019","unstructured":"Delcourt C, Gemival P, Nouhaud FX, Gobet F, Gillibert A, Ferlicot S, Sabourin JC, Irani J, Pfister C (2019) Clinical interest of PD-L1 immuno-histochemistry expression as a predictive factor of Bacillus Calmette Guerin (BCG) efficacy in refractory high-risk non-muscle-invasive bladder cancer (NMIBC). World J Urol. https:\/\/doi.org\/10.1007\/s00345-019-02896-3","journal-title":"World J Urol"},{"issue":"1","key":"3065_CR25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1001\/jamaoncol.2015.3638","volume":"2","author":"J McLaughlin","year":"2016","unstructured":"McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, Velcheti V, Herbst R, LoRusso P, Rimm DL (2016) Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol 2(1):46\u201354. https:\/\/doi.org\/10.1001\/jamaoncol.2015.3638","journal-title":"JAMA Oncol"},{"key":"3065_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/diseases7020044","author":"M Miyake","year":"2019","unstructured":"Miyake M, Hori S, Ohnishi S, Owari T, Iida K, Ohnishi K, Morizawa Y, Gotoh D, Itami Y, Nakai Y, Inoue T, Anai S, Torimoto K, Aoki K, Fujii T, Tanaka N, Fujimoto K (2019) Clinical impact of the increase in immunosuppressive cell-related gene expression in urine sediment during intravesical Bacillus Calmette-Guerin. Diseases. https:\/\/doi.org\/10.3390\/diseases7020044","journal-title":"Diseases"},{"key":"3065_CR27","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000355","author":"Y Lotan","year":"2019","unstructured":"Lotan Y, Inman BA, Davis LG, Kassouf W, Messing E, Daneshmand S, Canter D, Marble HT, Joseph AM, Jewell S, Boorjian SA (2019) Evaluation of the fluorescence in situ hybridization test to predict recurrence and\/or progression of disease after Bacillus Calmette-Guerin for primary high grade nonmuscle invasive bladder cancer: results from a prospective multicenter trial. J Urol. https:\/\/doi.org\/10.1097\/JU.0000000000000355","journal-title":"J Urol"},{"issue":"3","key":"3065_CR28","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, Carvalho BS, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ, Network TR, Weinstein JN, Kwiatkowski DJ, Lerner SP (2017) Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171(3):540\u2013556. https:\/\/doi.org\/10.1016\/j.cell.2017.09.007","journal-title":"Cell"},{"issue":"5","key":"3065_CR29","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.eururo.2018.06.045","volume":"74","author":"MF Chevalier","year":"2018","unstructured":"Chevalier MF, Schneider AK, Cesson V, Dartiguenave F, Lucca I, Jichlinski P, Nardelli-Haefliger D, Derre L (2018) Conventional and PD-L1-expressing regulatory T Cells are enriched during BCG therapy and may limit its efficacy. Eur Urol 74(5):540\u2013544. https:\/\/doi.org\/10.1016\/j.eururo.2018.06.045","journal-title":"Eur Urol"},{"issue":"2","key":"3065_CR30","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.eururo.2015.06.023","volume":"69","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, Briggman J, Urbauer DL, Svatek R, Nogueras Gonzalez GM, Anderson R, Grossman HB, Prat F, Dinney CP (2016) Cytokine panel for response to intravesical therapy (CyPRIT): Nomogram of changes in urinary cytokine levels predicts patient response to Bacillus Calmette-Guerin. Eur Urol 69(2):197\u2013200. https:\/\/doi.org\/10.1016\/j.eururo.2015.06.023","journal-title":"Eur Urol"},{"issue":"8","key":"3065_CR31","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1172\/JCI89717","volume":"127","author":"MF Chevalier","year":"2017","unstructured":"Chevalier MF, Trabanelli S, Racle J, Salome B, Cesson V, Gharbi D, Bohner P, Domingos-Pereira S, Dartiguenave F, Fritschi AS, Speiser DE, Rentsch CA, Gfeller D, Jichlinski P, Nardelli-Haefliger D, Jandus C, Derre L (2017) ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence. J Clin Invest 127(8):2916\u20132929. https:\/\/doi.org\/10.1172\/JCI89717","journal-title":"J Clin Invest"},{"issue":"9","key":"3065_CR32","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.jtho.2018.05.013","volume":"13","author":"MS Tsao","year":"2018","unstructured":"Tsao MS, Kerr KM, Kockx M, Beasley MB, Borczuk AC, Botling J, Bubendorf L, Chirieac L, Chen G, Chou TY, Chung JH, Dacic S, Lantuejoul S, Mino-Kenudson M, Moreira AL, Nicholson AG, Noguchi M, Pelosi G, Poleri C, Russell PA, Sauter J, Thunnissen E, Wistuba I, Yu H, Wynes MW, Pintilie M, Yatabe Y, Hirsch FR (2018) PD-L1 Immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol 13(9):1302\u20131311. https:\/\/doi.org\/10.1016\/j.jtho.2018.05.013","journal-title":"J Thorac Oncol"},{"key":"3065_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-018-2453-7","author":"L Zavalishina","year":"2018","unstructured":"Zavalishina L, Tsimafeyeu I, Povilaitite P, Raskin G, Andreeva Y, Petrov A, Kharitonova E, Rumyantsev A, Pugach I, Frank G, Tjulandin S (2018) RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer. Virchows Arch. https:\/\/doi.org\/10.1007\/s00428-018-2453-7","journal-title":"Virchows Arch"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-019-03065-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-019-03065-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-019-03065-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:18:53Z","timestamp":1609546733000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-019-03065-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,3]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["3065"],"URL":"https:\/\/doi.org\/10.1007\/s00345-019-03065-2","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,3]]},"assertion":[{"value":"5 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"We declare that there are no potential competing interests in this research.<b>Ethical standards<\/b>This study was conducted according to the Declaration of Helsinki and institutional review board approval (Approval no: GO 17\/400-16) was obtained on May 30, 2017.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}